Tag: fibrosis

Posted on by

Pulmonary Fibrosis Awareness Month Features Walks, Education and Events

Pulmonary Fibrosis Awareness Month Features Walks, Education and Events

CHICAGO, Aug. 30, 2022 /PRNewswire/ — The Pulmonary Fibrosis Foundation (PFF) will showcase how the pulmonary fibrosis (PF) community stands together in the fight against the life-threatening lung disease during Pulmonary Fibrosis Awareness Month in September.

“We will shine the spotlight on PF by sharing important facts about the disease and personal stories from individuals who are impacted by it, “said William T. Schmidt, president and CEO of the PFF. “We want everyone in the community to get involved, come to our events and spread the word.”

September is Pulmonary Fibrosis Awareness Month, presented by the Pulmonary Fibrosis Foundation as a way to drive awareness of pulmonary fibrosis. More than 250,000 Americans are living with pulmonary fibrosis, a serious lung disease that causes progressive scarring in the lungs. (Photo: The Pulmonary Fibrosis Foundation)
September is Pulmonary Fibrosis Awareness Month, presented by the Pulmonary Fibrosis Foundation as a way to drive awareness of pulmonary fibrosis. More than 250,000 Americans are living with pulmonary fibrosis, a serious lung disease that causes progressive scarring in the lungs. (Photo: The Pulmonary Fibrosis Foundation)

More than 250,000 Americans are living with PF, which causes progressive scarring in the lungs. More than 50,000 new cases are diagnosed annually in the U.S.

Community Events

The PFF Walk 2022 to raise awareness and funds for research and support of those living with PF is set for the following dates in September —

  • Sept. 10 – Diversey Harbor, Chicago
  • Sept. 17 – Crissy Field, Bay Area
  • Sept. 24 – National Walk Day, Virtually

The PFF Walk features two course options – 5K and one mile – and family-friendly activities, refreshments, educational materials about PF and more. Registration is free and those who raise $100 or more will receive a commemorative PFF Walk t-shirt.

The second annual ILD Day on Wednesday, Sept. 14, aims to elevate awareness of interstitial lung disease (ILD), of which there are 200 different causes. ILD is characterized by inflammation and/or scarring in the lungs, making it difficult to breathe and get oxygen into the blood stream.

As part of ILD Day, an educational webinar hosted by internationally recognized ILD expert, Dr. Anna Podolanczuk, will be held at 12 p.m. CDT on Sept. 14. The presentation will focus on “Progressive Pulmonary Fibrosis: What Patients Need to Know,” and will provide information to help patients better understand the disease and its progression. Webinar registration is available here.

Social Media

Beginning September 1, the PFF will post content every day on its social media channels with the handle @pfforg on Facebook, Twitter, Instagram, and YouTube, using the hashtags #PFMonth and #BlueUp4PF. Each day, a fact about PF will be posted at 11 a.m. CDT and a story will be posted at 1 p.m. CDT.

The #BlueUp4PF campaign recognizes the effect of the lack of oxygen in the bloodstream. Inadequate oxygen levels, which can be caused by PF, may result in the fingernails or lips turning a bluish color. #BlueUp4PF encourages people to wear blue, take a selfie, and post it on social media with the reason they are going blue for PF Awareness Month.

In addition, more than 100 iconic buildings, monuments and bridges will shine blue with hope for the PF community throughout September. The list of sites and the dates they will be illuminated during PF Awareness Month is available here.

About the Pulmonary Fibrosis Foundation

The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis. Until this goal is achieved, the PFF is committed to advancing improved care of patients with PF and providing unequaled support and education resources for patients, caregivers, family members, and health care providers. The PFF has a three-star rating from Charity Navigator and is an accredited charity by the Better Business Bureau (BBB) Wise Giving Alliance. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program® and has earned the Guidestar Platinum Seal of Transparency. For more information, visit pulmonaryfibrosis.org or call 844.TalkPFF (844.825.5733).

Contact: Dorothy Coyle
773-332-6201

SOURCE The Pulmonary Fibrosis Foundation

Posted on by

DAA use decreases risk for cardiovascular events in patients with advanced fibrosis, HCV

Healio Logo - Gastroenterology

Source:

Lam L, et al. Abstract OS006. Presented at: International Liver Congress; June 22-26, 2022; London (hybrid meeting).

Disclosures:
Healio was unable to confirm relevant financial disclosures at the time of publication.


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

LONDON — Direct-acting antiviral treatment correlated with a decreased risk for cardiovascular outcomes among patients with hepatitis C virus and advanced fibrosis but an increased risk for arrhythmias and conduction disorders.

“Several studies have revealed that hepatitis C virus can induce chronic inflammation and immune dysregulation, and this immune dysregulation and chronic inflammation explained the development of extrahepatic manifestations in chronic hepatitis C patients, including cardiovascular disease,” Laurent Lam, MD, a physician and doctoral researcher at the Pierre Louis Institute of Epidemiology and Public Health at Sorbonne University in Paris, told attendees at the International Liver Congress. “Few data are available regarding the long-term impact of DAAs on the occurrence of non-liver events.”

Using the prospective ANRS CO22 HEPATHER cohort, which derived individual data from the French National Health Insurance Database, Lam and colleagues analyzed 8,148 patients with chronic HCV between August 2012 and December 2015 for cardiovascular events and cancer incidence. The primary outcome was the association between DAA use and extrahepatic events.

Among 22,326 and 12,905 person-years of DAA and no DAA exposure, analysis showed DAA exposure correlated with a reduced risk for peripheral arterial disease (HR = 0.54; 95% CI, 0.33-0.89), an overall beneficial effect on cardiovascular among patients with HCV/advanced fibrosis (adjusted HR = 0.58; 95% CI, 0.42-0.79) and an increased risk for arrhythmias and conduction disorders (HR = 1.46; 95% CI, 1.04-2.04).

Lam and colleagues observed no association between DAA use and extrahepatic cancer (HR = 1.23; 95% CI, 0.5-3.03).

“Direct-acting antiviral exposure reduced the risk for peripheral arterial disease, overall cardiovascular events and increased risk for arrhythmias and conduction disorders,” Lam concluded. “Direct acting antivirals are not associated with extrahepatic cancer development or reduction in our study.”


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

International Liver Congress

International Liver Congress

Posted on by

Liver fibrosis linked to CV events, survival in NAFLD, chronic kidney disease

After a median follow-up of 10 years, NAFLD correlated with an increased risk for: “Variable A” – Cardiovascular events; HR = 1.39 “Variable B” – All-cause mortality; HR = 1.1

Source:

Hydes T, et al. Abstract OS048. Presented at: International Liver Congress; June 22-26, 2022; London (hybrid meeting).


Disclosures:
Hydes reports no relevant financial disclosures.


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

LONDON — Elevated noninvasive markers of liver fibrosis correlated with an increased risk for cardiovascular events, end-stage renal disease and worse survival in patients with chronic kidney disease and nonalcoholic fatty liver disease.

“Multimorbidity is increasing, and it is vital to understand the clinical consequences of having more than one medical condition,” Theresa Hydes, MBBS, BSc, PhD, NIHR clinical lecturer in hepatology at the University of Liverpool, told Healio. “Fatty liver disease, in particular, is independently associated with several non-liver conditions, including heart disease and chronic kidney disease.”


After a median follow-up of 10 years, NAFLD correlated with an increased risk for: “Variable A” – Cardiovascular events; HR = 1.39 “Variable B” – All-cause mortality; HR = 1.1



Seeking to assess the effect of NAFLD and NAFLD fibrosis on adverse clinical outcomes and mortality among patients with chronic kidney disease (CKD), Hydes and colleagues analyzed data from 26,074 patients using the UK Biobank. Participants provided information related to medical history, demographics and lifestyle factors, which was supplemented via electronic linkage to hospital records and death records.

Researchers used Cox regression to estimate hazard ratios associated with NAFLD and advanced liver fibrosis on CV events, progression to end-stage renal disease (ESRD) and all-cause mortality.

At baseline, 54,5% of patients with CKD had NAFLD, with evidence of advanced fibrosis among 7% [NAFLD fibrosis score (NFS) 0.676], 3.2% [elevated fibrosis-4 (FIB-4) > 2.67] and 1.1% [AST to platelet ratio index (APRI) 1].

After a median follow-up of 10 years, NAFLD correlated with an increased risk for CV events (HR = 1.39; 95% CI, 1.29-1.51) and all-cause mortality (HR = 1.1; 95% CI, 1.01-1.19) but not ESRD (HR = 1.22; 95% CI, 0.95-1.56) in a univariate analysis. Following multivariate adjustment for demographics, metabolic factors and baseline renal functions, NAFLD did not associate with an increased risk for primary outcomes.

Advanced liver fibrosis using all scores correlated with an increased risk for all-cause mortality (HR = 2.34-2.9), and NFS and FIB-4 associated with an elevated risk for CV events (HR = 2.49; 95% CI, 2.11-2.93 and HR = 1.94; 95% CI, 1.53-2.45) and ESRD (HR = 6.85; 95% CI, 4.29-10.94 and HR = 2.35; 95% CI, 1.19-4.67). After full adjustment, FIB-4 correlated with an increased incidence of CV events (HR = 1.39; 95% CI, 1.06-1.82), notably heart failure (HR = 1.65; 95% CI, 1.16-2.33).

Both FIB-4 and APRI associated with all-cause mortality (HR = 1.55; 95% CI, 1.21-2 and HR = 2.83; 95% CI, 1.95-4.11) and NFS ( –1.455) associated with progression to ESRD (HR = 1.89; 95% CI, 1.13-3.17).

“These results highlight the importance of enhanced recognition of fatty liver disease with fibrosis in people with chronic kidney disease to inform the need for vigorous cardiometabolic risk factor control in this group,” Hydes said. “It also suggests the need for work to understand the mechanisms linking these conditions to help drive new drug discoveries.”


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

International Liver Congress

International Liver Congress